Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2021

View Archived Issues

Potent selective pan-serotype dengue inhibitor developed

Discovery and preclinical characterization of novel TLR3 agonist, TL-532

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent ADCs including B7-H3 antibodies

New NLRP3 inflammasome inhibitors identified at Astellas Pharma

Atux Iskay presents new anticancer compounds

New TRK inhibitors divulged by J2H Biotech

Preclinical data presented for RP-3500

NVL-520 demonstrates efficacy in PDX models harboring ROS1 fusions

Regeneration of GABAergic neurons by in vivo reprogramming of glial cells reduces epileptic seizures

BRD9 is a druggable target for treating ccRCC with absent or low HIF-2alpha expression

ENPP1 inhibitor TXN-10128 shows promising antitumor activity trough restoration of STING activation

AavantiBio expands partnership with University of Florida to create gene therapy capsids

Creative Medical Technology announces proof-of-concept data on ImmCelz immunotherapy product

Hereditary Neuropathy Foundation and Rarebase partner to find treatments for Charcot-Marie Tooth

Poseida and Takeda partner on nonviral in vivo gene therapy programs

Amydis receives NINDS funding to explore presence of ASYN in retina of Parkinson's models

Kallistatin is a marker of NAFLD progression in patients with hypertension

NV-CoV-2 effective against SARS-CoV-2 in standard cell culture pseudovirion assay

Liver TR-beta1 activation can alleviate nonalcoholic steatohepatitis

NCI grant supports development of ST-316 to treat Wnt/beta-catenin-dependent breast cancer

Preclinical data support use of ibrexafungerp to treat mucormycosis

Emmaus gains license to Kainos' novel IRAK-4 inhibitor KM-10544

BridgeBio reports highlights from preclinical cancer and gene therapy pipelines

Vaxil reports data on P-Esbp-DOX in mouse model of aggressive liver metastasis of colorectal tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...